Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study - 03/12/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Many patients with hepatocellular carcinoma (HCC) have advance disease at diagnosis. |
• | Therapies used to treated advance HCC are the embolization TAE and TACE procedures. |
• | The study evaluated if addition of nitroglycerin to TAE or TACE improved outcomes. |
• | Addition of nitroglycerin did not improve overall survival or disease progression. |
Summary |
Background |
Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC.
Methods |
Patients with HCC either received (n=42) or did not receive (non-NTG) (n=111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored.
Results |
The rate of disease progression in the NTG group was 86.5% and in the non-NTG group was 88.6%. Median time to disease progression was 12 months (95% CI; 9.0, 15.0) for the NTG group and 12 months (95% CI; 10.4, 13.6) for the non-NTG groups (P=0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P=0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B.
Conclusions |
Addition of NTG to TAE/TACE did not result in improved OS or disease progression.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatocellular cancer, Nitroglycerine, Transarterial chemoembolization, Enhanced permeability retention, Overall survival, Disease progression
Plan
Vol 42 - N° 6
P. 542-552 - décembre 2018 Retour au numéro
Article précédent
- CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis
- Ye Zhou, Xue-bin Wang, Xue-ping Qiu, Chen Wang, Fang Zheng
- Surgical outcomes between patients with and without a cirrhotic liver undergoing laparoscopic liver resection: A meta-analysis
- Chunling Wang, Zhangkan Huang, Xiaozhun Huang, Caixia Liu, Zhanzhou Lin, Xuelan Lu, Fengxiang Shi, Biao Zheng, Shuisheng Zhang, Fanyuan Wen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?